» Articles » PMID: 38258045

Lipid-Based Nanotechnology: Liposome

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2024 Jan 23
PMID 38258045
Authors
Affiliations
Soon will be listed here.
Abstract

Over the past several decades, liposomes have been extensively developed and used for various clinical applications such as in pharmaceutical, cosmetic, and dietetic fields, due to its versatility, biocompatibility, and biodegradability, as well as the ability to enhance the therapeutic index of free drugs. However, some challenges remain unsolved, including liposome premature leakage, manufacturing irreproducibility, and limited translation success. This article reviews various aspects of liposomes, including its advantages, major compositions, and common preparation techniques, and discusses present U.S. FDA-approved, clinical, and preclinical liposomal nanotherapeutics for treating and preventing a variety of human diseases. In addition, we summarize the significance of and challenges in liposome-enabled nanotherapeutic development and hope it provides the fundamental knowledge and concepts about liposomes and their applications and contributions in contemporary pharmaceutical advancement.

Citing Articles

Nanotechnology and Artificial Intelligence in Dyslipidemia Management-Cardiovascular Disease: Advances, Challenges, and Future Perspectives.

Mlynarska E, Bojdo K, Frankenstein H, Kustosik N, Mstowska W, Przybylak A J Clin Med. 2025; 14(3).

PMID: 39941558 PMC: 11818864. DOI: 10.3390/jcm14030887.


Multi spectroscopic investigation of maisine-based microemulsions as convenient carriers for co-delivery of anticancer and anti-inflammatory drugs.

Nistor M, Nicolescu A, Amarandi R, Pui A, Stiufiuc R, Dragoi B Sci Rep. 2025; 15(1):5175.

PMID: 39939665 PMC: 11822113. DOI: 10.1038/s41598-025-89540-w.


The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases.

Okafor N, Omoteso O, Choonara Y Discov Nano. 2025; 20(1):19.

PMID: 39883380 PMC: 11782757. DOI: 10.1186/s11671-024-04170-x.


Innovative Approaches to Enhancing the Biomedical Properties of Liposomes.

Dejeu I, Vicas L, Marian E, Ganea M, Frent O, Maghiar P Pharmaceutics. 2025; 16(12.

PMID: 39771504 PMC: 11728823. DOI: 10.3390/pharmaceutics16121525.


Lipid Nanovesicles for Antioxidant Delivery in Skin: Liposomes, Ufasomes, Ethosomes, and Niosomes.

Ricci A, Stefanuto L, Gasperi T, Bruni F, Tofani D Antioxidants (Basel). 2025; 13(12.

PMID: 39765844 PMC: 11727561. DOI: 10.3390/antiox13121516.


References
1.
Maggio I, Zittersteijn H, Wang Q, Liu J, Janssen J, Ojeda I . Integrating gene delivery and gene-editing technologies by adenoviral vector transfer of optimized CRISPR-Cas9 components. Gene Ther. 2020; 27(5):209-225. PMC: 7253353. DOI: 10.1038/s41434-019-0119-y. View

2.
Kiaie S, Mojarad-Jabali S, Khaleseh F, Allahyari S, Taheri E, Zakeri-Milani P . Axial pharmaceutical properties of liposome in cancer therapy: Recent advances and perspectives. Int J Pharm. 2020; 581:119269. DOI: 10.1016/j.ijpharm.2020.119269. View

3.
Gu J, Liu C, Xie J, Ma B, Cui S, Yang G . The Local Anesthetic Bupivacaine Inhibits the Progression of Non-Small Cell Lung Cancer by Inducing Autophagy Through Akt/mTOR Signaling. Front Oncol. 2021; 11:616445. PMC: 7991299. DOI: 10.3389/fonc.2021.616445. View

4.
Andra V, Pammi S, Bhatraju L, Ruddaraju L . A Comprehensive Review on Novel Liposomal Methodologies, Commercial Formulations, Clinical Trials and Patents. Bionanoscience. 2022; 12(1):274-291. PMC: 8790012. DOI: 10.1007/s12668-022-00941-x. View

5.
Fassas A, Anagnostopoulos A . The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma. 2005; 46(6):795-802. DOI: 10.1080/10428190500052438. View